Literature DB >> 17339254

Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis.

Nimer Assy, Osamah Hussein, Zied Abassi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17339254      PMCID： PMC1856826          DOI： 10.1136/gut.2006.106021

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  8 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

2.  Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

Authors:  Elisabetta Bugianesi; Nicola Leone; Ester Vanni; Giulio Marchesini; Franco Brunello; Patrizia Carucci; Alessandro Musso; Paolo De Paolis; Lorenzo Capussotti; Mauro Salizzoni; Mario Rizzetto
Journal:  Gastroenterology       Date:  2002-07       Impact factor: 22.682

3.  Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial.

Authors:  Iris J Jonkers; Martina F Mohrschladt; Rudi G Westendorp; Arnoud van der Laarse; Augustinus H Smelt
Journal:  Am J Med       Date:  2002-03       Impact factor: 4.965

Review 4.  Medical management of obesity.

Authors:  Robert F Kushner
Journal:  Semin Gastrointest Dis       Date:  2002-07

5.  Treatment with orlistat reduces cardiovascular risk in obese patients.

Authors:  J H Zavoral
Journal:  J Hypertens       Date:  1998-12       Impact factor: 4.844

6.  Role of cytochrome P4502E1-dependent formation of hydroxyethyl free radical in the development of liver damage in rats intragastrically fed with ethanol.

Authors:  E Albano; P Clot; M Morimoto; A Tomasi; M Ingelman-Sundberg; S W French
Journal:  Hepatology       Date:  1996-01       Impact factor: 17.425

Review 7.  Diet composition and the metabolic syndrome: what is the optimal fat intake?

Authors:  Scott M Grundy; Nicola Abate; Manisha Chandalia
Journal:  Am J Med       Date:  2002-12-30       Impact factor: 4.965

8.  Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.

Authors:  M H Davidson; J Hauptman; M DiGirolamo; J P Foreyt; C H Halsted; D Heber; D C Heimburger; C P Lucas; D C Robbins; J Chung; S B Heymsfield
Journal:  JAMA       Date:  1999-01-20       Impact factor: 56.272
  8 in total
  19 in total

Review 1.  Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine.

Authors:  Mazen Noureddin; José M Mato; Shelly C Lu
Journal:  Exp Biol Med (Maywood)       Date:  2015-04-13

2.  Combination drug treatment in patients with non-alcoholic fatty liver disease.

Authors:  Theodosios D Filippatos; Moses S Elisaf
Journal:  World J Hepatol       Date:  2010-04-27

Review 3.  Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease.

Authors:  Michael S Kostapanos; Anastazia Kei; Moses S Elisaf
Journal:  World J Hepatol       Date:  2013-09-27

Review 4.  Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link.

Authors:  Abby B Siegel; Andrew X Zhu
Journal:  Cancer       Date:  2009-12-15       Impact factor: 6.860

5.  Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes.

Authors:  Alok K Gupta; George A Bray; Frank L Greenway; Corby K Martin; William D Johnson; Steven R Smith
Journal:  J Diabetes Complications       Date:  2009-07-04       Impact factor: 2.852

6.  Current treatments in nonalcoholic steatohepatitis.

Authors:  Dawn M Torres; Stephen A Harrison
Journal:  Curr Treat Options Gastroenterol       Date:  2007-12

7.  Liver histology changes in nonalcoholic steatohepatitis after one year of treatment with probucol.

Authors:  Shahin Merat; Mohsen Aduli; Rozana Kazemi; Masoud Sotoudeh; Nahid Sedighi; Masoud Sohrabi; Reza Malekzadeh
Journal:  Dig Dis Sci       Date:  2007-11-30       Impact factor: 3.199

8.  Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease.

Authors:  Sahar Mohamed El-Haggar; Tarek Mohamed Mostafa
Journal:  Hepatol Int       Date:  2015-05-09       Impact factor: 6.047

Review 9.  A complications-based clinical staging of obesity to guide treatment modality and intensity.

Authors:  Sunil Daniel; Taraneh Soleymani; W Timothy Garvey
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2013-10       Impact factor: 3.243

10.  Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study.

Authors:  Vassilios G Athyros; Olga Giouleme; Emmanouel S Ganotakis; Moses Elisaf; Konstantinos Tziomalos; Themistoklis Vassiliadis; Evangelos N Liberopoulos; Eleni Theocharidou; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  Arch Med Sci       Date:  2011-11-08       Impact factor: 3.318
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.